Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.59 |
| ▸ | RELA | Q04206 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3625738 | 0.83 | MEN1 (0.77) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL16222829 | 0.83 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL14422990 | 0.81 | MEN1 (0.82) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL2434792 | 0.77 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL1227061 | 0.77 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL28643702 | 0.77 | MEN1 (0.56) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL1198719 | 0.77 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3558330 | 0.76 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL28663547 | 0.74 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL3781325 | 0.74 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101657471-B | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP | 2013-07-03 | — | — | CN | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101657471-A | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP US | 2010-02-24 | — | — | CN | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-100491323-C | Biaryloxymethylarenecarboxylic acids compound | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| CN-1812956-A | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
| EP-0643119-B1 | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition | SUMITOMO CHEMICAL CO (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-6030546-A | FERROELECTRIC PHASE; LOW VISCOSITY;, THERMOSENSITIVITY OVER A BROAD AND EXHIBITS A LARGE TILT ANGLE AND A HIGH-SPEED RESPONSE PROPERTY;CHEMICAL INTERMEDIATES FOR PESTICIDES, DRUGS AND LIQUID CRYSTALS; BORIDING AND HYDROLYSIS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5707547-A | CONTAINING FLUORINATED BENZENE OR NAPHTHALENE RINGS AND/OR NITROGEN CONTAINING HETEROCYCLES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0643119-A1 | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
| EP-0256097-B1 | VINYL COMPOUNDS AND LIQUID CRYSTAL PHASE | MERCK PATENT GmbH (DE) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | NPC1 479/4885RAB9A 2962/4885SMN1; SMN2 4188/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | NPC1 479/4885RAB9A 2962/4885SMN1; SMN2 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.